Article
S100A9 Promotes Resistance to Anti-PD-1 Immunotherapy in Hepatocellular Carcinoma by Degrading PARP1 and Activating the STAT3/PD-L1 Pathway
2025-01-14
Abstract excerpt
<title>Abstract</title> <p>Background Immune checkpoint inhibitors (ICIs), such as anti-programmed cell death protein-1 (PD-1) immunotherapy, have emerged as promising treatments for advanced hepatocellular carcinoma (HCC), significantly improving clinical outcomes. However, resistance to ICIs remains a major challenge, and the underlying mechanisms of this resistance are not yet fully understood. This study aim...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 7afdfc6d-7f3b-55c3-b259-0b208239a3d2
- DOI
- 10.21203/rs.3.rs-5797937/v1
